Drug intelligence / Profile preview

l-[1-13C]leucine

Development stage
Preclinical
Lead developer
Cambridge Isotope Laboratories
Modality
Small Molecules
Administration
Intravenous
01

Overview

l-[1-13C]leucine is a stable isotope-labeled variant of the essential branched-chain amino acid L-leucine, where the carbon atom at the carboxyl (C1) position is replaced with the non-radioactive carbon-13 isotope. It is primarily used as a metabolic tracer in clinical research to quantify protein turnover, specifically the fractional synthesis rate (FSR) of proteins in various tissues such as skeletal muscle. By measuring the enrichment of the isotope in plasma, intracellular pools (like alpha-ketoisocaproate), and incorporated protein via mass spectrometry, researchers can calculate rates of protein synthesis, breakdown, and oxidation. This tracer is particularly valuable in studying muscle-wasting conditions, metabolic disorders, and the effects of aging or disease on protein metabolism, as it allows for safe, non-invasive tracking of amino acid kinetics in humans.

Other names
13C-leucine[1-13C]leucineL-leucine-1-13CL-leucine1-13CL-leucine 1-13C1-13C-L-leucineL-[1-13C]leucine
02

Targets

BCKDH complex (Branched-chain alpha-keto acid dehydrogenase complex)aaRS (Aminoacyl-tRNA synthetase family)

Beyond the preview

Go deeper on l-[1-13C]leucine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-[1-13C]leucine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call